What is the equity of CureVac this year?
CureVac has equity of 516.94 M EUR this year.
CureVac Equity 2025
CureVac Equity
516.94 M EUR
Ticker
CVAC
ISIN
NL0015436031
WKN
A2P71U
In 2025, CureVac's equity was 516.94 M EUR, a -3.07% increase from the 533.3 M EUR equity in the previous year.
CureVac Aktienanalyse
What does CureVac do?
CureVac NV is a German biotechnology company that was founded in 2000 by Ingmar Hoerr, who still leads the company today. The company is headquartered in Tübingen and has a branch in Frankfurt am Main. CureVac's goal is to develop and produce innovative therapies to combat diseases. The history of CureVac began with a focus on the development of RNA-based therapeutics. RNA is a molecule that plays a central role in protein production within the cell. By using RNA in therapeutic applications, the body's own processes can be utilized to fight diseases. CureVac has successfully developed a variety of RNA-based therapeutics in recent years, which are in various stages of clinical development. CureVac's business model is based on providing its technology platform to other companies. These companies can use the platform to develop their own RNA-based therapeutics. CureVac receives fees for this service and also receives a share of any revenues resulting from these projects. CureVac also operates its own pipeline of therapeutic products based on various technologies. One important technology, for example, is the use of messenger RNA (mRNA) to produce proteins that can have a therapeutic effect. CureVac has entered into several partnerships with large pharmaceutical companies such as Sanofi and Boehringer Ingelheim to bring its products to market. The company benefits from the strength of its technology platform and its ability to develop new methods for the production of RNA-based therapeutics. Furthermore, CureVac has played an important role in containing the global COVID-19 pandemic. The company has developed an mRNA vaccine against the SARS-CoV-2 virus, which is approved in Europe. The vaccine has shown to be particularly effective and has a high efficacy against the various variants of the virus. CureVac has signed a contract with the European Union for the delivery of up to 405 million doses of its COVID-19 vaccine, making it an important partner in the fight against the pandemic. Overall, CureVac is a company with a strong focus on RNA-based therapeutics. The company has successfully built a strong technology platform in recent years, enabling other companies to develop their own RNA-based therapeutics. At the same time, CureVac has built its own pipeline of products in various stages of clinical development. The company benefits from the strength of its technology platform and its ability to develop sustainable and effective solutions for various diseases. The success of CureVac, particularly its role in the fight against the COVID-19 pandemic, has shown that RNA technology will play an important role in the future of biotechnology. CureVac ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing CureVac's Equity
CureVac's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding CureVac's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating CureVac's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
CureVac's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in CureVac’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about CureVac stock
What was the equity of CureVac compared to the previous year?
The equity of CureVac has increased/decreased by -3.07% decreased compared to the previous year.
What impact does a high equity have on investors of CureVac?
A high equity is advantageous for investors of CureVac as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of CureVac?
A low equity can be a risk for investors of CureVac, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of CureVac affect the company?
An increase in equity of CureVac can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of CureVac affect the company?
A reduction in equity of CureVac can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of CureVac?
Some factors that can affect the equity of CureVac include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of CureVac so important for investors?
The equity of CureVac is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can CureVac take to change the equity?
To change equity, CureVac can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does CureVac pay?
Over the past 12 months, CureVac paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CureVac is expected to pay a dividend of 0 EUR.
What is the dividend yield of CureVac?
The current dividend yield of CureVac is .
When does CureVac pay dividends?
CureVac pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of CureVac?
CureVac paid dividends every year for the past 0 years.
What is the dividend of CureVac?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is CureVac located?
CureVac is assigned to the 'Health' sector.
Wann musste ich die Aktien von CureVac kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of CureVac from 3/7/2025 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 3/7/2025.
When did CureVac pay the last dividend?
The last dividend was paid out on 3/7/2025.
What was the dividend of CureVac in the year 2024?
In the year 2024, CureVac distributed 0 EUR as dividends.
In which currency does CureVac pay out the dividend?
The dividends of CureVac are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The CureVac stock can be added to a savings plan with the following providers: Scalable Capital
Andere Kennzahlen von CureVac
Our stock analysis for CureVac Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CureVac Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
